argenx SE (ARGX) Stock Forecast, Price Target & Predictions
ARGX Stock Forecast
argenx SE stock forecast is as follows: an average price target of $475.14 (represents a -15.79% downside from ARGX’s last price of $564.23) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.
ARGX Price Target
The average price target for argenx SE (ARGX) is $475.14 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $715.00 to $326.27. This represents a potential -15.79% downside from ARGX's last price of $564.23.
ARGX Analyst Ratings
According to 20 Wall Street analysts, argenx SE's rating consensus is 'Buy'. The analyst rating breakdown for ARGX stock is 1 'Strong Buy' (5.00%), 17 'Buy' (85.00%), 2 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
argenx SE Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | George Farmer | Scotiabank | $715.00 | $602.47 | 18.68% | 26.72% |
| Oct 10, 2024 | Danielle Brill | Raymond James | $605.00 | $520.52 | 16.23% | 7.23% |
| Jul 29, 2024 | Joel Beatty | Robert W. Baird | $515.00 | $495.92 | 3.85% | -8.73% |
| Jul 26, 2024 | Douglas Tsao | H.C. Wainwright | $533.00 | $492.06 | 8.32% | -5.53% |
| Jul 23, 2024 | Leland Gershell | Oppenheimer | $546.00 | $461.01 | 18.44% | -3.23% |
| Jul 22, 2024 | Joon Lee | Truist Financial | $540.00 | $461.01 | 17.13% | -4.29% |
| Jul 12, 2024 | Gavin Clark-Gartner | Evercore ISI | $533.00 | $461.72 | 15.44% | -5.53% |
| Jun 26, 2024 | Douglas Tsao | H.C. Wainwright | $490.00 | $451.55 | 8.52% | -13.16% |
| Jun 24, 2024 | Joon Lee | Truist Financial | $480.00 | $441.15 | 8.81% | -14.93% |
| Jun 24, 2024 | George Farmer | Scotiabank | $416.00 | $437.96 | -5.01% | -26.27% |
The latest argenx SE stock forecast, released on Nov 05, 2024 by George Farmer from Scotiabank, set a price target of $715.00, which represents a 18.68% increase from the stock price at the time of the forecast ($602.47), and a 26.72% increase from ARGX last price ($564.23).
argenx SE Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 14 |
| Avg Price Target | $715.00 | $660.00 | $524.86 |
| Last Closing Price | $564.23 | $564.23 | $564.23 |
| Upside/Downside | 26.72% | 16.97% | -6.98% |
In the current month, the average price target of argenx SE stock is $715.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 26.72% increase as opposed to argenx SE's last price of $564.23. This month's average price target is up 8.33% compared to last quarter, and up 36.23% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2024 | Wolfe Research | - | Outperform | Upgrade |
| Nov 05, 2024 | Scotiabank | Sector Perform | Outperform | Upgrade |
| Nov 01, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Nov 01, 2024 | William Blair | Outperform | Outperform | Upgrade |
| Oct 17, 2024 | Wedbush | Underperform | Underperform | Hold |
| Oct 17, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 17, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 04, 2024 | Deutsche Bank | Buy | Hold | Downgrade |
| Sep 26, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
argenx SE's last stock rating was published by Wolfe Research on Nov 11, 2024. The company Upgrade its ARGX rating from "null" to "Outperform".
argenx SE Financial Forecast
argenx SE Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $219.14M | $174.16M | $23.41M | $158.16M | $11.47M | $40.94M | $6.87M | $18.56M |
| Avg Forecast | $629.67M | $599.65M | $484.13M | $409.26M | $376.23M | $346.95M | $292.61M | $22.24M | $15.01M | $23.36M | $210.64M | $9.37M | $73.12M | $5.08M | $29.70M |
| High Forecast | $699.52M | $664.57M | $534.82M | $452.12M | $415.63M | $354.65M | $323.25M | $26.68M | $18.01M | $28.03M | $252.77M | $11.24M | $87.74M | $6.10M | $35.64M |
| Low Forecast | $575.33M | $549.13M | $433.01M | $366.06M | $336.51M | $316.34M | $261.72M | $17.79M | $12.00M | $18.69M | $168.51M | $7.50M | $58.49M | $4.06M | $23.76M |
| # Analysts | 7 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
| Surprise % | - | - | - | - | - | - | - | 9.85% | 11.61% | 1.00% | 0.75% | 1.22% | 0.56% | 1.35% | 0.63% |
argenx SE's average Quarter revenue forecast for Sep 23 based on 10 analysts is $292.61M, with a low forecast of $261.72M, and a high forecast of $323.25M. ARGX's average Quarter revenue forecast represents a 33.53% increase compared to the company's last Quarter revenue of $219.14M (Mar 23).
argenx SE EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
| EBITDA | - | - | - | - | - | - | - | $-87.16M | $-100.51M | $-221.91M | $-29.25M | $-157.21M | $7.78M | $-21.77M | $-390.75K |
| Avg Forecast | $-479.61M | $-456.74M | $-368.75M | $-311.73M | $-205.90M | $-264.27M | $-222.88M | $-217.62M | $-61.43M | $-228.63M | $-38.96M | $-85.62M | $13.90M | $-10.73M | $-625.20K |
| High Forecast | $-438.23M | $-418.26M | $-329.82M | $-278.82M | $-164.72M | $-240.95M | $-199.35M | $-174.10M | $-49.15M | $-182.90M | $-31.16M | $-68.50M | $16.68M | $-8.59M | $-500.16K |
| Low Forecast | $-532.82M | $-506.20M | $-407.37M | $-344.37M | $-247.08M | $-270.13M | $-246.22M | $-261.15M | $-73.72M | $-274.36M | $-46.75M | $-102.75M | $11.12M | $-12.88M | $-750.24K |
| Surprise % | - | - | - | - | - | - | - | 0.40% | 1.64% | 0.97% | 0.75% | 1.84% | 0.56% | 2.03% | 0.63% |
16 analysts predict ARGX's average Quarter EBITDA for Sep 20 to be $-85.62M, with a high of $-68.50M and a low of $-102.75M. This is -1200.38% lower than argenx SE's previous annual EBITDA (Mar 19) of $7.78M.
argenx SE Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
| Net Income | - | - | - | - | - | - | - | $-28.87M | $-38.61M | $-227.19M | $-40.43M | $-157.66M | $7.58M | $-26.10M | $-387.55K |
| Avg Forecast | $112.70M | $70.51M | $5.94M | $-55.15M | $-204.16M | $-74.13M | $-87.12M | $-215.79M | $-61.74M | $-226.70M | $-53.85M | $-85.87M | $13.54M | $-10.73M | $-620.07K |
| High Forecast | $163.92M | $142.22M | $6.75M | $-47.58M | $-163.33M | $-38.57M | $-75.17M | $-172.63M | $-49.39M | $-181.36M | $-43.08M | $-68.70M | $16.24M | $-8.59M | $-496.06K |
| Low Forecast | $4.22M | $-2.41M | $5.12M | $-62.66M | $-245.00M | $-156.69M | $-98.98M | $-258.95M | $-74.08M | $-272.04M | $-64.62M | $-103.05M | $10.83M | $-12.88M | $-744.09K |
| Surprise % | - | - | - | - | - | - | - | 0.13% | 0.63% | 1.00% | 0.75% | 1.84% | 0.56% | 2.43% | 0.63% |
argenx SE's average Quarter net income forecast for Sep 20 is $-85.87M, with a range of $-103.05M to $-68.70M. ARGX's average Quarter net income forecast represents a -1232.99% decrease compared to the company's last Quarter net income of $7.58M (Mar 19).
argenx SE SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
| SG&A | - | - | - | - | - | - | - | $149.17M | $135.29M | $100.87M | $56.25M | $74.57M | $12.70M | $7.27M | $2.13M |
| Avg Forecast | $928.46M | $884.20M | $713.86M | $603.47M | $90.64M | $511.59M | $431.47M | $32.79M | $22.13M | $34.45M | $74.92M | $13.82M | $22.68M | $3.58M | $3.40M |
| High Forecast | $1.03B | $979.93M | $788.61M | $666.66M | $108.77M | $522.94M | $476.65M | $39.35M | $26.55M | $41.34M | $89.90M | $16.58M | $27.21M | $4.30M | $4.08M |
| Low Forecast | $848.35M | $809.70M | $638.49M | $539.76M | $72.51M | $466.46M | $385.92M | $26.23M | $17.70M | $27.56M | $59.94M | $11.05M | $18.14M | $2.87M | $2.72M |
| Surprise % | - | - | - | - | - | - | - | 4.55% | 6.11% | 2.93% | 0.75% | 5.40% | 0.56% | 2.03% | 0.63% |
argenx SE's average Quarter SG&A projection for Sep 23 is $431.47M, based on 10 Wall Street analysts, with a range of $385.92M to $476.65M. The forecast indicates a 189.24% rise compared to ARGX last annual SG&A of $149.17M (Mar 23).
argenx SE EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
| EPS | - | - | - | - | - | - | - | $-0.52 | $-0.70 | $-4.36 | $-0.81 | $-3.16 | $0.20 | $-0.81 | $-0.01 |
| Avg Forecast | $1.71 | $1.07 | $0.09 | $-0.84 | $-0.72 | $-1.13 | $-1.32 | $1.31 | $1.78 | $1.29 | $-4.16 | $-1.30 | $-1.33 | $-0.19 | $-0.60 |
| High Forecast | $2.49 | $2.16 | $0.10 | $-0.72 | $-0.62 | $-0.59 | $-1.14 | $1.49 | $2.02 | $1.29 | $-3.33 | $-1.04 | $-1.06 | $-0.15 | $-0.47 |
| Low Forecast | $0.06 | $-0.04 | $0.08 | $-0.95 | $-0.82 | $-2.38 | $-1.51 | $1.13 | $1.53 | $1.29 | $-5.01 | $-1.56 | $-1.58 | $-0.23 | $-0.71 |
| Surprise % | - | - | - | - | - | - | - | -0.40% | -0.39% | -3.38% | 0.19% | 2.43% | -0.15% | 4.34% | 0.02% |
According to 16 Wall Street analysts, argenx SE's projected average Quarter EPS for Sep 20 is $-1.30, with a low estimate of $-1.56 and a high estimate of $-1.04. This represents a -751.30% decrease compared to ARGX previous annual EPS of $0.20 (Mar 19).
argenx SE Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| ZLAB | Zai Lab | $27.06 | $75.50 | 179.01% | Buy |
| TERN | Terns Pharmaceuticals | $6.17 | $14.25 | 130.96% | Buy |
| LEGN | Legend Biotech | $38.19 | $82.69 | 116.52% | Buy |
| AKRO | Akero Therapeutics | $28.09 | $46.00 | 63.76% | Buy |
| ASND | Ascendis Pharma | $126.51 | $190.21 | 50.35% | Buy |
| PCVX | Vaxcyte | $86.83 | $124.00 | 42.81% | Buy |
| BGNE | BeiGene | $189.23 | $255.80 | 35.18% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| TVTX | Travere Therapeutics | $17.72 | $21.75 | 22.74% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| ALNY | Alnylam Pharmaceuticals | $235.56 | $254.21 | 7.92% | Buy |
| ARGX | argenx SE | $564.23 | $475.14 | -15.79% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |